NEOPLASIAS HEMATOLÓGICAS: LEUCEMIAS, LINFOMAS Y MIELOMAS

VolverVolver

Resultados 76 resultados LastUpdate Última actualización 23/03/2019 [15:04:00] pdf PDF

Solicitudes publicadas en los últimos 30 días / Applications published in the last 30 days

Página1 de 4 nextPage   por página


SECURININE AND NORSECURININE ANALOGUE COMPOUNDS FOR THE TREATMENT OF MYELOID DISORDERS

NºPublicación: US2019083472A1 21/03/2019

Solicitante:

UNIV CASE WESTERN RESERVE [US]

Resumen de: US2019083472A1

The present application relates to securinine or norsecurinine analogues that, when administered to immature myeloid cells, promote differentiation of these cells to mature cells that do not readily proliferate. Therefore, the agents are useful in the treatment of myeloid disorders including myeloproliferative disorders, acute myeloid leukemia, and autoimmune diseases. The agents may also be used as a myeloablative agent in conjunction with a bone marrow transplant or stem cell therapy.

traducir

BROMODOMAIN AND EXTRA-TERMINAL PROTEIN INHIBITOR COMBINATION THERAPY

NºPublicación: US2019083483A1 21/03/2019

Solicitante:

CELGENE QUANTICEL RES INC [US]

TW_201821106_A

Resumen de: US2019083483A1

The present disclosure relates generally to compositions and methods of treating neoplastic diseases or cancers, such as glioblastoma and non-Hodgkin's lymphomas, or other cancers in which the subject suffers from an advanced solid tumor, comprising a combination of, or administering a combination of, a bromodomain and extra-terminal protein (BET) inhibitor and at least one chemotherapeutic agent, which does not inhibit BET directly. The BET inhibitor/chemotherapeutic agent combination, or combination therapy, can yield synergistic effects, thereby increasing the effectiveness of the cancer treatment as compared with the administration of either the BET inhibitor or the chemotherapeutic agent alone.

traducir

EFFICACY OF ANTI-HLA-DR ANTIBODY DRUG CONJUGATE IMMU-140 (hL243-CL2A-SN-38) IN HLA-DR POSITIVE CANCERS

NºPublicación: US2019083487A1 21/03/2019

Solicitante:

IMMUNOMEDICS INC [US]

US_2017360770_PA

Resumen de: US2019083487A1

The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an anti-HLA-DR antibody or antigen-binding antibody fragment. The immunoconjugate may be administered at a dosage of between 3 mg/kg and 18 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg, more preferably 8, 10 or 12 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. The methods and compositions are particularly useful for treating AML, ALL or multiple myeloma.

traducir

IN-VITRO INDUCTION OF ADULT STEM CELL EXPANSION AND DERIVATION

NºPublicación: US2019085335A1 21/03/2019

Solicitante:

LIN SHI LUNG [US]
CHANG LIN SAMANTHA [US]
CHANG DONALD [US]

Resumen de: US2019085335A1

This invention generally relates to a composition and its method of use for inducing adult stem cell (ASC) expansion and/or derivation in vitro, using miR-302-like pre-miRNAs, shRNAs and/or siRNAs, all of which contain a shared sequence of 5′-UAAGUGCUUC CAUGUUU-3′ (SEQ ID NO: 7) in the 5′-end, and further in conjunction with the use of some wound-healing-related defined factors, including but not limited to basic fibroblast growth factor (bFGF)/fibroblast growth factor 2 (FGF-2), leukemia inhibitory factor (LIF), insulin-like growth factor (IGF), Epidermal growth factor (EGF), platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), transforming growth factor (TGF), tumor necrosis factor (TNF), stem cell factor (SCF), homeobox proteins (HOX), Notch, GSK, Wnt/beta-Catenin signals, interleukins, and/or bone morphogenetic proteins (BMPs). The principle of the present invention is related to a novel mechanism of inducible symmetric ASC division recently found in a skin wound healing model in vivo. The resulting amplified ASCs are useful for treating a variety of human aging- and cell dysfunction-associated disorders, including but not limited to Alzheimer's disease, Parkinson's disease, motor neuron disease, stroke, diabetes, osteoporosis, myocardial infraction, hemophilia, anemia, AIDS, leukemia, lymphoma and many kinds of cancers as well as aging.

traducir

COMBINATION TREATMENT FOR CANCER

NºPublicación: WO2019053613A2 21/03/2019

Solicitante:

GLAXOSMITHKLINE IP DEV LTD [GB]

Resumen de: WO2019053613A2

Disclosed herein is a method of treating cancer, such as multiple myeloma, involving the combination of an anti-BCMA antigen binding protein (e.g., an anti-BCMA antibody) and an immunomodulatory agent (e.g. an agent directed to ICOS or an anti-CD38 antigen binding protein).

traducir

METHODS AND COMPOSITIONS FOR GENETICALLY MODIFYING AND EXPANDING LYMPHOCYTES AND REGULATING THE ACTIVITY THEREOF

NºPublicación: WO2019055946A1 21/03/2019

Solicitante:

F1 ONCOLOGY INC [US]

Resumen de: WO2019055946A1

The present disclosure provides methods and compositions for genetically modifying lymphocytes and related methods that include genetically modifying T cells and/or NK cells. The methods use replication incompetent recombinant retroviral particles that comprise a pseudotyping element on their surface and optionally a membrane-bound T cell activation element, such as an anti-CD3, and encode one or more engineered signaling polypeptides that can include a lymphoproliferative element, and/or a chimeric antigen receptor (CAR). The methods can include contacting PBMCs with replication incompetent recombinant retroviral particles for various exemplary time periods, such as less than 24 hours or in some illustrative embodiments less than 15 minutes. Illustrative chimeric lymphoproliferative elements that are capable of promoting survival and/or proliferation of T cells or NK cells in culture without adding IL-2, are provided. Furthermore, additional regulatory elements are provided, such as inhibitory RNA molecules.

traducir

METHODS FOR IDENTIFYING MYELOMA TUMOR-INITIATING CELLS AND TARGETED THERAPY

NºPublicación: WO2019055930A1 21/03/2019

Solicitante:

UNIV IOWA RES FOUND [US]

Resumen de: WO2019055930A1

In certain embodiments, the present invention provides a method of treating cancer in a patient comprising administering an effective amount of a therapeutic agent to the patient, wherein the cancer was determined to contain cells comprising cell marker CD24+. In certain embodiments, the cancer cells also comprise cell markers CD38+ and/or CD45-.

traducir

COMBINATION TREATMENT FOR CANCER

NºPublicación: WO2019053611A1 21/03/2019

Solicitante:

GLAXOSMITHKLINE IP DEV LTD [GB]

Resumen de: WO2019053611A1

Disclosed herein is a method of treating cancer, such as multiple myeloma, involving the combination of an anti-BCMA antigen binding protein (e.g., an anti-BCMA antibody) and a proteasome inhibitor (e.g. bortezomib). The combinations can also include an anti-inflammatory compound (e.g. dexamethasone).

traducir

COMBINATION TREATMENT FOR CANCER

NºPublicación: WO2019053612A1 21/03/2019

Solicitante:

GLAXOSMITHKLINE IP DEV LTD [GB]

Resumen de: WO2019053612A1

Disclosed herein is a method of treating cancer, such as multiple myeloma, involving the combination of an anti-BCMA antigen binding protein (e.g., an anti-BCMA antibody) and an immunomodulatory drug (e.g. pomalidomide or lenalidomide). The combinations can also include an anti-inflammatory compound (e.g. dexamethasone).

traducir

TREATMENT METHOD

NºPublicación: WO2019051541A1 21/03/2019

Solicitante:

DENDROCYTE BIOTECH PTY LTD [AU]

Resumen de: WO2019051541A1

The present invention relates to a method of treating lymphoma in a subject, and more particularly, for treating Hodgkin lymphoma (HL), and non-Hodgkin lymphoma (NHL). The method comprises administering to the subject an effective amount of a CD83 binding protein. The invention also relates to methods for diagnosing and assessing lymphoma in a subject.

traducir

NOVEL BIOMARKERS FOR ACUTE MYELOID LEUKEMIA

NºPublicación: EP3457138A2 20/03/2019

Solicitante:

UNIV MONTREAL [CA]
UNIV LAVAL [CA]

US_2016060709_A1

Resumen de: EP3457138A2

Methods for the diagnosis of leukemias, and more specifically AML, such as MLL-AF9 AML, in a subject, based on the assessment of the expression or activity of one or more of the genes listed in Tables 1 and 2 are disclosed. The use of antibodies or antigen-binding fragments thereof that bind to one or more of proteins showing preferential expression at the cell surface of AML leukemic cells for treating AML is also disclosed.

traducir

USE OF THE TELOMERASE INHIBITOR IMETELSTAT FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROME

NºPublicación: EP3456333A1 20/03/2019

Solicitante:

GERON CORP [US]

MA_38193_B1

Resumen de: EP3456333A1

Provided herein are methods for reducing neoplastic progenitor cell proliferation and alleviating symptoms associated in individuals diagnosed with or thought to have myelodysplastic syndrome. Also provided herein are methods for using telomerase inhibitors for maintaining blood platelet counts at relatively normal ranges in the blood of individuals diagnosed with or suspected of having myelodysplastic syndrome.

traducir

MONITORING SOLID TRANSPLANT REJECTION USING CLONOTYPE PROFILES

NºPublicación: EP3456847A1 20/03/2019

Solicitante:

ADAPTIVE BIOTECHNOLOGIES CORP [US]

JP_2018068300_A

Resumen de: EP3456847A1

There is a need for improved methods for determining the diagnosis and prognosis of patients with conditions, including autoimmune disease and cancer, especially lymphoid neoplasms, such as lymphomas and leukemias. Provided herein are methods for using DNA sequencing to identify personalized, or patient-specific biomarkers in patients with lymphoid neoplasms, autoimmune disease and other conditions. Identified biomarkers can be used to determine and/or monitor the disease state for a subject with an associated lymphoid disorder or autoimmune disease or other condition. In particular, the invention provides a sensitive method for monitoring lymphoid neoplasms that undergo clonal evolutions without the need to development alternative assays for the evolved or mutated clones serving as patient-specific biomarkers.

traducir

IMMUNE-CHECKPOINT INHIBITORS FOR USE IN THE TREATMENT OF BLOOD-BORNE CANCERS

NºPublicación: US2019077869A1 14/03/2019

Solicitante:

AMGEN RES MUNICH GMBH [DE]

JP_2018531215_A

Resumen de: US2019077869A1

The present invention provides an inhibitor against CD112 (Nectin-2, PVRL2), CD155 (PVR), Galectin-9, TIM-3 and/or TIGIT for use in a method of treatment of a blood-borne cancer, in particular acute myeloid leukemia (AML). Moreover, the present invention provides a pharmaceutical composition comprising an inhibitor against CD112 (Nectin-2, PVRL2), CD155 (PVR), Galectin-9, TIM-3 and/or TIGIT and a CAR T cell. The present invention further provides a pharmaceutical composition comprising an inhibitor against CD112 (Nectin-2, PVRL2), CD155 (PVR), Galectin-9, TIM-3 and/or TIGIT and an antibody construct that is capable of engaging T cells.

traducir

TREATMENT OF LEUKEMIA VIA THE ADMINISTRATION OF DOT1L INHIBITOR PINOMETOSTAT

NºPublicación: US2019076455A1 14/03/2019

Solicitante:

EPIZYME INC [US]

WO_2016090271_A1

Resumen de: US2019076455A1

The present invention relates to a method for the treatment of leukemia and the induction of leukemic blast cell maturation or differentiation via the administration of the DOT1L inhibitor pinometostat (otherwise known as EPZ-5676; CAS Registry number 1380288-87-8) or its N-oxide or pharmaceutically acceptable salt thereof.

traducir

GENERATION AND PROFILING OF FULLY HUMAN HuCAL GOLD-DERIVED THERAPEUTIC ANTIBODIES SPECIFIC FOR HUMAN CD38

NºPublicación: US2019077877A1 14/03/2019

Solicitante:

MORPHOSYS AG [DE]

ES_2653664_T3

Resumen de: US2019077877A1

The present invention provides novel antibodies and methods for using recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These methods take advantage of newly discovered antibodies and surprising properties of such antibodies, such as the ability to bind CD38 of minipig origin and the ability to induce, by cross-linking, specific killing of cells that express CD38. These antibodies as well as the novel methods for using those antibodies can be used to treat, for example, hematological malignancies such as multiple myeloma.

traducir

CLINICAL ASSESSMENT OF M-PROTEIN RESPONSE IN MULTIPLE MYELOMA

NºPublicación: US2019077875A1 14/03/2019

Solicitante:

MORPHOSYS AG [DE]

KR_20180118151_A

Resumen de: US2019077875A1

Applicant discloses an anti-idiotypic antibody to MOR202, which when fused to human albumin, shifted the anti-body in IFE thus mitigating any potential interference of MOR202 with the M-protein clinical assessment.

traducir

COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF CANCER

NºPublicación: US2019076545A1 14/03/2019

Solicitante:

UTI LP [CA]

US_2017274096_A1

Resumen de: US2019076545A1

Conventional cancer immunotherapy falls short at efficiently expanding T cells that specifically target cancerous cells in numbers sufficient to significantly reduce the tumor size or cancerous cell number in vivo. To overcome this limitation, provided herein are nanoparticles coated with MHC class I and/or class II molecules presenting tumor-specific antigens and co-stimulatory molecules and their use to expand antigen-specific anti-tumorigenic T cells to levels not achieved in current immunotherapeutic techniques. These antigen-specific anti-tumorigenic T cells include cytotoxic T cells, effector T cells, memory T cells, and helper T cells that are necessary to initiate and maintain a substantial immune response against metastatic or non-metastatic cancerous, pre-cancerous, or neoplastic cells in vivo. The present invention describes a systemic approach to targeting cancerous or pre-cancerous cells that are circulating cells, as in lymphomas, migratory metastatic cells, and solid tumors.

traducir

NOVEL CELL EPITOPES AND COMBINATION OF CELL EPITOPES FOR USE IN THE IMMUNOTHERAPY OF MYELOMA AND OTHER CANCERS

NºPublicación: US2019077832A1 14/03/2019

Solicitante:

IMMATICS BIOTECHNOLOGIES GMBH [DE]

MA_41521_A1

Resumen de: US2019077832A1

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer, in particular myeloma. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

traducir

NEW TREATMENTS OF MULTIPLE MYELOMA

NºPublicación: WO2019048679A1 14/03/2019

Solicitante:

IDP DISCOVERY PHARMA S L [ES]
FUNDACION DE INVESTIGACION DEL CANCER UNIV DE SALAMANCA [ES]

Resumen de: WO2019048679A1

The present invention relates to the field of oncology. More specifically, it relates to the use of peptidomimetic compounds in the treatment of multiple myeloma, especially in refractory or relapsing multiple myeloma and/or in combination with other antitumoral agents.

traducir

APPLICATION OF ANTI-PL2L60 PROTEIN ANTIBODY IN PREPARING ANTI-TUMOR DRUG AND METHOD FOR TREATING TUMORS

NºPublicación: WO2019047520A1 14/03/2019

Solicitante:

SHANGHAI YIFANKE BIOTECHNOLOGY CO LTD [CN]

CN_109464669_A

Resumen de: WO2019047520A1

Provided in the present invention is an application of a reagent that inhibits the ectopic expression of the PIWIL2 gene and an anti-PIWIL2 gene ectopic expression protein antibody in preparing an anti-tumor drug. Further provided by the present disclosure are an anti-tumor pharmaceutical composition and a method for treating tumors. It has been demonstrated by means of experimentation that treating human or mouse tumor cells by using KAO3 at the time of inoculation may inhibit the generation of tumors in mice. In addition, injecting KAO3 into established lymphoma, breast cancer, lung cancer, and cervical cancer may inhibit tumor growth and prolong the survival of tumor-bearing mice. The inhibitory effect of KAO3 is associated with KAO3-specific antigens expressed on the surface of tumor cells. KAO3 induces tumor cell apoptosis by means of stopping the cell cycle, inhibiting DNA synthesis, and activating a complement during the G2/M phase.

traducir

COMBINATION OF AN INHIBITOR OF PARP WITH AN INHIBITOR OF GSK-3 OR DOT1L

NºPublicación: US2019076427A1 14/03/2019

Solicitante:

KING S COLLEGE LONDON [GB]

WO_2017077326_A1

Resumen de: US2019076427A1

Provided herein is a pharmaceutical combination comprising (a) a poly-(ADP-ribose)-polymerase (PARP) inhibitor and (b) a second agent comprising (i) an inhibitor of glycogen synthase kinase 3 (GSK-3) or (ii) an inhibitor of disrupter of telomeric silencing 1-like (DOT1L). Also provided is a method of treating a subject suffering from acute myeloid leukaemia, comprising administering to the subject a therapeutically effective amount of the pharmaceutical combination. There is also described herein a method for selecting a therapy for a subject suffering from acute myeloid leukaemia, comprising determining whether a chromosomal abnormality at 11q23 is present in a sample obtained from the subject; wherein if the chromosomal abnormality at 11q23 is present in the sample, a therapy comprising combined administration of (a) a poly-(ADP-ribose)-polymerase (PARP) inhibitor and (b) a second agent comprising (i) an inhibitor of glycogen synthase kinase 3 (GSK-3) or (ii) an inhibitor of disrupter of telomeric silencing 1-like (DOT1L)is selected for the subject.

traducir

DOSING REGIMENS OF BI-SPECIFIC CD123 X CD3 DIABODIES IN THE TREATMENT OF HEMATOLOGIC MALIGNANCIES

NºPublicación: WO2019050521A1 14/03/2019

Solicitante:

MACROGENICS INC [US]

Resumen de: WO2019050521A1

The present invention is directed to a dosing regimen for administering a CD123 x CD3 bi-specific monovalent diabody to patients with a hematologic malignancy such as acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The invention particularly concerns the use of such a regimen for the sequence-optimized CD 123 x CD3 bi-specific monovalent diabody "DART-A," that is capable of simultaneous binding to CD 123 and CD3.

traducir

METHOD FOR IDENTIFYING CLINICAL TRIAL RESPONDERS FROM A PLACEBO GROUP IN MAJOR DEPRESSION

NºPublicación: US2019078161A1 14/03/2019

Solicitante:

TEKADA PHARMACEUTICAL COMPANY LTD [JP]

CA_3017749_A1

Resumen de: US2019078161A1

The present invention provides methods and kits for identifying clinical trial responders from a placebo group in clinical trials for treating depression and/or major depressive disorder (MDD). The present invention further provides methods and kits for treating depression and/or MDD in an individual, and for identifying the likelihood that an individual suffering from depression and/or MDD will respond favorably to administration of a placebo and/or experience an enhanced placebo effect when administered a placebo. These methods and kits comprise determining the presence of polymorphisms in the Brain-Derived Neurotrophic Factor gene (BDNF), the B-Cell CLL/Lymphoma 2 gene (BCL2), and/or intergenic regions in an individual.

traducir

TCRs specific for minor histocompatibility (H) antigen HA-1 and uses thereof

Nº publicación: AU2017331362A1 14/03/2019

Solicitante:

HUTCHINSON FRED CANCER RES

WO_2018058002_PA

Resumen de: AU2017331362A1

The present disclosure provides compositions and methods for targeting a minor histocompatibility (H) antigen (HA-1H?) to, for example, prevent or manage relapse of a hematological malignancy after allogeneic hematopoietic stem cell transplantation (HCT). Also provided are transgene constructs encoding engineered binding proteins, such as a T cell receptor or a chimeric antigen receptor, optionally encoding additional components such as a co-receptor and/or safety switch. Such transgene constructs can be transduced into an immune cell, such as a T cell, and used as an immunotherapy in a subject having a hematological malignancy or at risk for recurrence of the hematological malignancy (e.g., leukemia, lymphoma, myeloma).

traducir

Página1 de 4 nextPage por página

punteroimgVolver